Fig. 8: Sample total protein and tau protein mass spectrometry input. | Nature Communications

Fig. 8: Sample total protein and tau protein mass spectrometry input.

From: Specific post-translational modifications of soluble tau protein distinguishes Alzheimer’s disease and primary tauopathies

Fig. 8: Sample total protein and tau protein mass spectrometry input.The alternative text for this image may have been generated using AI.

a Soluble fraction proteins (top panel) and soluble tau (bottom panel) protein input were constant across all sample. b Aggregated proteins input was constant across all injected samples, but aggregated tau input varied by subject, justifying normalizing PTM abundances in the aggregates on the absolute quantity of aggregated tau, measured using the tau microtubule-binding repeat (MTBR, known to be the main part of tau sequence that aggregates). c Absolute levels of the tau protein Microtubule-binding region (MTBR) across all studied groups. In a and b each box represents a different subject (n = 44 biologically independent samples) and in c, each box represents a different condition (AD Alzheimer’s disease (n = 7 subjects), CBD corticobasal degeneration (n = 5 subjects), PiD Pick’s disease (n = 5 subjects), FTLD frontotemporal lobe degeneration (n = 10 subjects, including FTLD-4R, n = 4 and FTLD-3R, n = 6), CTL control individuals (n = 5)). The line inside the box denotes the median value (50th percentile), while the box contains the 25th to 75th percentiles of dataset. The whiskers mark the 5th and 95th percentiles, and values beyond these upper and lower bounds are considered outliers. Data are available via ProteomeXchange with identifier PXD038901.

Back to article page